Autopsy report · NCT05849246

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

“strategy terminates development, the decision is not due to any safety-related issues”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 5 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Sponsor type

Industry

Conditions

Non-squamous Non-small-cell Lung Cancer

Interventions

Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed; Sintilimab+Carboplatin or Cisplatin+Pemetrexed; Tusamitamab ravtansine+Sintilimab

Participants

4

Sites

1

Countries

China

Trials that died the same way

• A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump
  “The decision to terminate development activities was based on business needs and unrelated to any safety or efficacy concerns.” (74% match in meaning)
• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
  “The development was stopped due to company's strategy consideration” (73% match in meaning)
• A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
  “It has been made the strategic decision to terminate the study. This decision to terminate the study early is not being made for safety reasons.” (72% match in meaning)
• Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
  “Decision based on strategic determination; not safety.” (70% match in meaning)
• A Single and Multiple Ascending Dose Study of JNJ-64457744
  “Strategic business decision, not due to safety concerns” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.